• Picard C, Nilsson N, Labonté A, Auld D, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative, Ashton NJ, Zetterberg H, Blennow K, Breitner JCB, Villeneuve S, Poirier J; PREVENT-AD research group. Apolipoprotein B is a novel marker for early tau pathology in Alzheimer’s disease. Alzheimers Dement. 2021 Sep 29. [full text]
  • Gonneaud J, Baria AT, Pichet Binette A, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M, Gauthier S, Benzinger TLS, Morris JC, Bateman RJ, Breitner JCS, Poirier J, Vachon-Presseau E, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN) Study Group; Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease (PREVENT-AD) Research Group. Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease. Nat Commun. 2021 Sep 9;12(1):5346. [full text]
  • Tremblay-Mercier J, Madjar C, Das S, Pichet Binette A, Dyke SOM, Étienne P, Lafaille-Magnan ME, Remz J, Bellec P, Collins DL, Rajah MN, Bohbot V, Leoutsakos JM, Iturria-Medina Y, Kat J, Hoge RD, Gauthier S, Tardif CL, Chakravarty M, Poline JB, Rosa-Neto P, Evans AC, Villeneuve S, Poirier J, Breitner JCS; PREVENT-AD Research Group. Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease. Neuroimage Clin. 2021;31:102733. [full text]
  • Pichet Binette A, Theaud G, Rheault F, Roy M, Collins DL, Levin J, Mori H, Lee JH, Farlow MR, Schofield P, Chhatwal JP, Masters CL, Benzinger T, Morris J, Bateman R, Breitner JC, Poirier J, Gonneaud J, Descoteaux M, Villeneuve S; DIAN Study Group; PREVENT-AD Research Group. Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease. Elife. 2021 May 13;10:e62929. [full text]
  • Köbe T, Pichet Binette A, Vogel JW, Meyer PF, Breitner JCS, Poirier J, Villeneuve S; for the PREVENT-AD Research Group. Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer’s disease: Vascular risk factors and functional connectivity changes. NeuroImage. 2021;231:117832. [full text]
  • Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, Palmqvist S, Mattsson-Carlgren N, Olsson T, Jögi J, Stormrud E, Ryu YH, Choi JY; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD research group, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Villeneuve S, Lyoo CH, Rabinovici GD, Hansson O. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2245-2258. [full text]


  • Gonneaud J, Bedetti C, Pichet Binette A, Benzinger TLS, Morris JC, Bateman RJ, Poirier J, Breitner JCS, Villeneuve S; DIAN Study Group and the PREVENT-AD Research Group. Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease. Neurology. 2020;95(11):e1554-e1564. [abstract]
  • Marchant NL, Lovland LR, Jones R, Pichet Binette A, Gonneaud J, Arenaza-Urquijo EM, Chételat G, Villeneuve S; PREVENT-AD Research Group. Repetitive negative thinking is associated with amyloid, tau, and cognitive decline. Alzheimers Dement.. 2020;16(7):1054-1064. [full text]
  • Pichet Binette A, Vachon-Presseau E, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve, S; Dominantly Inherited Alzheimer Network (DIAN) and the PREVENT-AD Research Group. Amyloid and tau pathology associations with personality traits, neuropsychiatric factors and cognitive lifestyle in the preclinical phases of sporadic and autosomal dominant Alzheimer’s disease. Biological Psychiatry. 2020;S0006-3223(20)30058-5. [abstract]
  • Köbe T, Gonneaud J, Pichet Binette A, Meyer P-F, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; for the PREVENT-AD Research Group. Association of vascular risk factors with amyloid-β peptide and tau burdens in cognitively unimpaired individuals and its interaction with vascular medication use. JAMA Network Open. 2020;3(2):e1920780. [full text]
  • Meyer P-F, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurology. 2020;77(4):508-516. [full text]
  • Pichet Binette A, Gonneaud J, Poirier J, Vogel JW, La Joie R, Rosa-Neto P, Collins DL, Poirier J, Breitner JCS, Villeneuve S*, Vachon-Presseau E*; Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD Research Group. Morphometric network differences in ageing versus Alzheimer’s disease dementia. Brain. 2020;143(2):635-649.
    *Indicates authors that contributed equally to this work.
    [full text]
  • McSweeney M*, Pichet Binette A*, Meyer P-F, Gonneaud J, Bedetti C, Ozlen H, Labonté A, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S, for the PREVENT-AD Research Group. Intermediate flortaucipir uptake is associated with Aβ-PET and CSF-tau in asymptomatic adults. Neurology. 2020;94(11):e1190-e1200.
    *Indicates authors that contributed equally to this work.
    [abstract, pdf]


  • Villeneuve S. Lifespan Cognitive Reserve—A Secret to Coping With Neurodegenerative Pathology. JAMA Neurology. 2019; 76:1145-1146. [abstract]
  • Meyer P-F, McSweeney M, Gonneaud J, Villeneuve S. PET amyloid imaging across the Alzheimer’s disease spectrum: From disease mechanisms to prevention. Progress in Molecular Biology and Translational Science. 2019;165:63-106. [abstract, pdf]
  • DeCarli C, Villeneuve S, Maillard P, Harvey D, Singh B, Carmichael O, Fletcher E, Olichney J, Farias S, Jagust W, Reed B, Mungas D. Vascular burden score impacts cognition independent of amyloid PET and MRI measures of Alzheimer’s disease and vascular brain injury. J Alzheimers Dis. 2019;68:187-196. [abstract, pdf]
  • Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O*, Ossenkoppele R*, for the Alzheimer’s Disease Neuroimaging Initiative and the Swedish BioFINDER study. Data-driven approaches for tau-PET biomarkers in Alzheimer’s disease. Hum Brain Mapp. 2019;40:638-665. [full text, pdf]


  • Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD Research Group. Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease, Brain. 2018;141:1871-1883. [full text, pdf]
  • Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; PREVENT-AD Research Group. Proximity to parental symptom onset and amyloid-β burden in sporadic Alzheimer disease. JAMA Neurology. 2018;75:608–619. [full text, pdf]
  • Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD research group. Subjective cognitive decline is associated with altered default mode network connectivity in individuals with a family history of Alzheimer’s Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2018;3:463-472. [abstract, pdf]


  • Mander B, Zhu A, Lindquist J, Villeneuve S, Rao V, Lu B, Saletin J, Ancoli-Israel S, Jagust W, Walker M. White matter structure in older adults moderates the benefit of sleep spindles on motor memory consolidation. J Neurosci. 2017;37:11675-11687. [full text, pdf]
  • Boudjemeline M, Hopewell R, Rochon PL, Jolly D, Hammami I, Villeneuve S, Kostikov A. Highly efficient solid phase-supported radiosynthesis of [11 C]PiB using tC18 cartridge as a “3-in-1” production entity. J Labelled Comp Radiopharm. 2017;60(14):632-638. [full text, pdf]
  • Villeneuve S. Potential utility of practice effects in preventive trials. The Journal of Prevention of Alzheimer’s Disease. 2017;4(3):140-142. [pdf]
  • Grothe MJ, Villeneuve S, Dyrba M, Bartrés-Faz D, Wirth M; Alzheimer’s Disease Neuroimaging Initiative. Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology. 2017;88:569-576. [full text, pdf]
  • Seo SW*, Ayakta N*, Grinberg LT, Villeneuve S, Lehmann M, Reed B, DeCarli C, Miller BL, Rosen HJ, Boxer AL, O’Neil JP, Jin LW, Seeley WW, Jagust WJ, Rabinovici GD. Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage: Clinical. 2017;13:130-137. [full text, pdf]
  • Orban P, Tam A, Urchs S, Savard M, Madjar C, Badhwar A, Dansereau C, Vogel JW, Shmuel A, Dagher A, Villeneuve S, Poirier J, Rosa-Neto P, Breitner J, Bellec P, for the Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD program. Subtypes of functional brain connectivity as early markers of neurodegeneration in Alzheimer’s disease. bioRxiv 195164. 2017. [full text, pdf]


  • Villeneuve S. Cause of suspected non-Alzheimer disease pathophysiology: If not tau pathology, then what? JAMA Neurology. 2016;73(10):1177-1179. [abstract, pdf]
  • Fletcher E, Villeneuve S, Maillard P, Harvey D, Reed B, Jagust W, DeCarli C. β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals. Neurobiol Aging. 2016;40:173-80. [abstract, pdf]


  • Villeneuve S, Brisson D, & Gaudet D. Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality. Journal of Lipids. 2015;2015: Article ID 742408. [full text, pdf]
  • Villeneuve S*, Rabinovici G*, Cohn-Sheehy B, Madison C, Ayakta N, Ghosh PM, Madison C, La Joie R, Arthur-Bentil SK, Vogel J, Marks S, Lehmann M, Rosen H, Reed B, Olichney J, DeCarli C, Miller BL, Borys E, Grinberg LT, Jin LW, Seeley WW & Jagust W. Existing PIB Thresholds are Too High: Statistical and Pathological Examination. Brain. 2015;138:2020-2033. [full text, pdf]
    *Indicates authors that contributed equally to this work.
  • Villeneuve S, Wirth M & La Joie R. Are AD-typical regions the convergence point of multiple pathologies? Front Aging Neurosci. 2015;7:42. [full text, pdf]
  • Villeneuve S & Jagust W. Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment. J Prev Alz Dis. 2015;2:64-70. [abstract, pdf]


  • Villeneuve S, Reed B, Madison C, Wirth M, Kriger S, Marchant N, Mack W, Sanossian N, DeCarli C, Chui H, Weiner M & Jagust W. Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions. Neurology. 2014;83:1-8. [abstract, pdf]
  • Villeneuve S, Brisson D, Marchant N & Gaudet D. The potential application of Apolipoprotein E in personalized medicine. Front Aging Neurosci. 2014;6:154. [full text, pdf]
  • Wirth M, Villeneuve S, La Joie R, Marks S. & Jagust W. Gene–Environment interactions: Lifetime cognitive activity, APOE genotype, and beta-amyloid burden. J Neurosci. 2014;34:8612-8617. [full text, pdf]
  • Wirth M, Haase C, Villeneuve S, Vogel J & Jagust W. Neuroprotective Pathways: Lifestyle activity, brain pathology and cognition in cognitively normal older adults. Neurobiol Aging. 2014;35:1873-1882. [abstract, pdf]
  • Villeneuve S, Reed BR, Wirth M, Haase CM, Madison CM, Ayakta N, Mack W, Mungas D, Chui HC, DeCarli C, Weiner M & Jagust W. Cortical thickness mediates the impact of β-amyloid on episodic memory. Neurology. 2014;82:761-762. [abstract, pdf]
  • Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurology. 2014;71:195-200. [full text, pdf]


  • Wirth M, Villeneuve S, Madisona C, Oh H, Rabinovici G & Jagust W. Associations between Alzheimer’s disease biomarkers, neurodegeneration, and cognition in normal older people. JAMA Neurol. 2013;70:1512-1519. [abstract, pdf]
  • Peters S, Villeneuve S & Belleville S. Predicting Progression to Dementia in Elderly Subjects with Mild Cognitive Impairment Using Both Cognitive and Neuroimaging Predictors. J Alzheimer Dis. 2013;38:307-318. [abstract, pdf]
  • Chao LL, DeCarli C, Kriger S, Truran D, Zhang Y, Laxamana J, Villeneuve S, Jagust WJ, Sanossian N, Mack W, Chui HC & Weiner MW. Associations between white matter hyperintensities and β amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLOSone. 2013;8:e65175. [abstract, pdf]
  • Villeneuve S, Pepin V, Gosselin N, Gagnon K & Gagnon J-F. Response to: Influence of OSA on cognitive impairment in patients with COPD. CHEST. 2013;143:1512-1513. [abstract, pdf]
  • Oh H, Madison C, Villeneuve S, Markley C & Jagust W. Association of gray matter atrophy with age, β-amyloid, and cognition in aging. Cerebral Cortex. 2014;24(6):1609-18. Epub ahead of print 2013. [abstract, pdf]


  • Villeneuve S, Pépin V, Rahayel S, Bertrand J-A, Delorimier M, Desjardins C, Rizk A, Parenteau S, Beaucage F, Joncas S, Monchi O & Gagnon J-F. Mild cognitive impairment in moderate to severe chronic obstructive pulmonary disease. CHEST. 2012; 142:1516-1523. [abstract, pdf]
  • Villeneuve S & Belleville S. The nature of memory failure in mild cognitive impairment: examining association with neurobiological markers and effect of progression, Neurobiol Aging. 2012; 33:1967-1978. [abstract, pdf]


  • Villeneuve S, Massoud F, Bocti C, Gauthier S & Belleville S. The nature of episodic memory deficits in MCI with and without vascular burden, Neuropsychologia. 2011; 49:3027-3035. [abstract, pdf]
  • Hudon C, Villeneuve S & Belleville S. The effect of semantic orientation at encoding on free recall performance in amnestic mild cognitive impairment and probable Alzheimer’s disease. J Clin Expe Neuropsychol. 2011; 33:631-638.
    [abstract, pdf]
  • Villeneuve S, Postuma RB, Joncas S, Latreille V, Rodrigues-Brazete J, Desjardin C & Gagnon J-F. Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson’s disease and REM sleep behavior disorder., Dement Geriatr Cogn Disord. 2011; 31:210-217. [abstract, pdf]
  • Ouellet C, Melançon L & Villeneuve S. Symptômes neuropsychiatriques et interventions cognitives chez les personnes avec trouble cognitif léger. Revue québ. Psychol. 2011; 32:35-56. [abstract]

2010 and earlier

  • Villeneuve S & Belleville S. Cognitive reserve and neuronal changes associated with aging. Psychol Neuropsychiatr du Vieil., 2010; 8:133-140. [abstract, pdf]
  • Belleville S, Villeneuve S, Peters F & Protat S. Vascular burden, cognition and aging. Revue de neuropsychologie, 2010; 2:1-8. [abstract, pdf]
  • Villeneuve S, Belleville S, Massoud F, Bocti C & Gauthier S. Impact of vascular risk factors and diseases on cognition in persons with mild cognitive impairment. Dement Geriatr Cogn Disord. 2009; 27:375-381. [abstract, pdf]
  • Belleville S & Villeneuve S. Aspects neuropsychologiques de la démence vasculaire. Actualités sur les démences : Aspects Cliniques et Neuropsychologiques, Édition Solal : mai 2006. [Book]

DISCLAIMER: The documents distributed here have been provided as a means to ensure timely dissemination of scholarly and technical work on a noncommercial basis. Copyright and all rights therein are maintained by the authors or by other copyright holders, notwithstanding that they have offered their works here electronically. It is understood that all persons copying this information will adhere to the terms and constraints invoked by each author’s copyright and or other publishers (as appropriate). These works may not be reposted without the explicit permission of the copyright holder.